UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

Journal of clinical oncology, 2010-05, Vol.28 (14), p.2381-2388

2010

Link zum Volltext

Verfügbarkeit prüfen

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma

BMC cancer, 2022-03, Vol.22 (1), p.231-231, Article 231

2022

Link zum Volltext

Verfügbarkeit prüfen

Application of camera phones in telehaematology

Journal of telemedicine and telecare, 2009-10, Vol.15 (7), p.339

2009

Link zum Volltext

Verfügbarkeit prüfen

Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

Blood, 2022-11, Vol.140 (Supplement 1), p.9528-9529

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Clinical cancer research, 2019-08, Vol.25 (15), p.4634-4643

2019

Link zum Volltext

Verfügbarkeit prüfen

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Haematologica (Roma), 2019-12, Vol.104 (12), p.2400-2409

2019

Link zum Volltext

Verfügbarkeit prüfen

Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies

Epigenetics, 2013-04, Vol.8 (4), p.445-454

2013

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

Advances in therapy, 2022-01, Vol.39 (1), p.598-618

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Fatigue in Previously Untreated CLL Patients with Comorbidities Treated with Obinutuzumab (GA101) + Chlorambucil (GClb) or Rituximab + Chlorambucil (RClb)

Blood, 2016-12, Vol.128 (22), p.2401-2401

2016

Link zum Volltext

Verfügbarkeit prüfen

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Blood, 2019-11, Vol.134 (Supplement_1), p.2788-2788

2019

Link zum Volltext

Verfügbarkeit prüfen

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Blood, 2016-12, Vol.128 (22), p.1223-1223

2016

Link zum Volltext

Verfügbarkeit prüfen

Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Blood, 2016-12, Vol.128 (22), p.4352-4352

2016

Link zum Volltext

Verfügbarkeit prüfen

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Blood, 2017-12, Vol.130, p.1740-1740

2017

Link zum Volltext

Verfügbarkeit prüfen

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

American journal of hematology, 2019-09, Vol.94 (9), p.1002-1006

2019

Link zum Volltext

Verfügbarkeit prüfen

Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease?

Digestive diseases and sciences, 2004-09, Vol.49 (9), p.1425-1432

2004

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide DNA methylation in chronic myeloid leukaemia

Bazeos, Alexandra

2016

Link zum Volltext
ProQuest

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

Haematologica (Roma), 2014-05, Vol.99 (5), p.797-801

2014

Link zum Volltext

Verfügbarkeit prüfen

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML

Blood, 2009-11, Vol.114 (22), p.3248-3248

2009

Link zum Volltext

Verfügbarkeit prüfen

HIV-associated Castleman's disease: from case reports to evidence

Journal of HIV therapy, 2007-09, Vol.12 (3), p.61

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Application of camera phones in telehaematology

Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

Evaluation of Fatigue in Previously Untreated CLL Patients with Comorbidities Treated with Obinutuzumab (GA101) + Chlorambucil (GClb) or Rituximab + Chlorambucil (RClb)

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL)

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease?

Genome-wide DNA methylation in chronic myeloid leukaemia

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML

HIV-associated Castleman's disease: from case reports to evidence

Suchergebnisse filtern